Neuroendocrine Tumor Grade 2
8
5
7
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
12.5%
1 terminated out of 8 trials
0.0%
-86.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
CapTemY90 for Grade 2/3 NET Liver Metastases
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors